E. Kutarska

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

M. M. Heiss, P. Murawa, P. Koralewski et al. · International Journal of Cancer · 2010 · 547 citations · Full text

Tumor Biology, Medicine, Puncture-free Survival +12

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

R. Wendel Naumann, Robert L. Coleman, Robert A. Burger et al. · Journal of Clinical Oncology · 2013 · 227 citations

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Ursula A. Matulonis, Sudarshan Sharma, Michael S. Gordon et al. · Gynecologic Oncology · 2012 · 134 citations

Oncology, Medicine, Pathology +8

Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer

Nicoletta Colombo, E. Kutarska, Meletios Α. Dimopoulos et al. · Journal of Clinical Oncology · 2012 · 120 citations

A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

Patricia Pautier, Ignace Vergote, Florence Joly et al. · International Journal of Gynecological Cancer · 2016 · 38 citations · Full text